Cargando…

Durable biochemical response following adrenal metastasectomy for oligometastatic castrate-resistant prostate cancer

A 77 year-old man was referred to Urology with an enlarging left adrenal mass after treatment with androgen deprivation therapy for metastatic castrate-resistant prostate cancer. He underwent a robotic-assisted left radical adrenalectomy, with pathology revealing metastatic adenocarcinoma consistent...

Descripción completa

Detalles Bibliográficos
Autores principales: Ashrafi, Akbar N., Fay, Carlos, Yip, Wesley, de Freitas, Daniel M., Nabhani, Jamal, Aron, Monish
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7217987/
https://www.ncbi.nlm.nih.gov/pubmed/32420037
http://dx.doi.org/10.1016/j.eucr.2020.101229
Descripción
Sumario:A 77 year-old man was referred to Urology with an enlarging left adrenal mass after treatment with androgen deprivation therapy for metastatic castrate-resistant prostate cancer. He underwent a robotic-assisted left radical adrenalectomy, with pathology revealing metastatic adenocarcinoma consistent with a primary prostate adenocarcinoma. The patient had a durable oncological response to metastasectomy with no evidence of biochemical or radiological recurrence after 5 years of follow-up. Adrenal metastases from prostate cancer are extremely rare, representing only 1% of metastatic cases. Surgical resection of oligometastatic prostate cancer recurrences may be considered in select patients and may improve progression-free survival.